Policy Discussions to Strengthen Bio Investment Ecosystem: Analyzing Major Countries' Strategies and Exploring Domestic Revitalization Measures

The National Bio Committee Support Group is ramping up policy discussions aimed at strengthening the investment foundation of South Korea's bio industry.

On December 9, the Support Group held a "Policy Roundtable for Strengthening the Bio Investment Ecosystem" at the National Bio Committee conference room in Seoul Square, focusing on reviewing major countries' investment promotion strategies and exploring ways to revitalize the domestic sector.

Photo to aid understanding of the article. Photo by The Asia Business Daily DB

원본보기 아이콘

At the roundtable, which was attended by representatives from policy and investment institutions, participants shared cases of bio investment promotion from the United States, China, and Japan, and discussed the structural constraints and improvement measures for Korea's bio investment environment. Attendees commonly pointed out that the full cycle from technology development to clinical trials and commercialization is not sufficiently connected, and that the institutional foundation for activating private investment remains inadequate.

Shin Kwangmin, Director at the Korea Biotechnology Industry Organization, said, "The domestic bio industry faces limitations in making significant strides due to insufficient capital circulation and a lack of global new drug development experience."

An Jihyun, Team Leader at Korea Investment Partners, and Yoon Heejung, Team Leader at the Korea Institute of S&T Evaluation and Planning (KISTEP), emphasized, "To enter the United States, the world's largest market, it is essential to secure capabilities for local clinical trials, regulatory approval, and sales. China has rapidly grown by establishing a development model from the outset that presumes entry into the U.S. market, and we should also take this as a reference."

Jeon Hwanjoo, Team Leader at the Korea Health Industry Development Institute (KHIDI), explained, "Japan has consistently maintained a foundation for new drug exports by strengthening its venture ecosystem targeting the global market from the early stages."

Jin Seungha, Director of Bio Investment Strategy at the National Bio Committee Support Group, stated, "For promising pipelines owned by domestic companies to translate into global success, more systematic support is needed. Based on today's discussions, we will work to establish a practical investment ecosystem foundation and enhance global competitiveness."

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.